Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

OBJECTIVE: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared out...

Descripción completa

Detalles Bibliográficos
Autores principales: Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J.V., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur V., Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Novel Communications in Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385469/
https://www.ncbi.nlm.nih.gov/pubmed/34183431
http://dx.doi.org/10.2337/dc21-0300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385469/
https://www.ncbi.nlm.nih.gov/pubmed/34183431
http://dx.doi.org/10.2337/dc21-0300

Ejemplares similares